Rugo H, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol. 2016;34:3069-3103. Abstract
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Breast cancer, v2. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Updated April 6, 2017. Accessed June 12, 2017.
Cardoso F, Costa A, Senkus E, et al. 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3). Annals of Oncology. 2017;28:16-33. Abstract
Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30:2718-2724. Abstract
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520-529. Abstract
Cristofanelli M, Turner N, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet. 2016;17:425-439. Abstract
Freedman R, Tolaney S. Efficacy and safety in elderly patient subsets across studies investigating endocrine monotherapy versus combination therapy in patients with HR+/HER2-advanced breast cancer. Poster presented at: American Society of Clinical Oncology (ASCO); June 2-6, 2017; Chicago, IL. Abstract 1045.
Pritchard KI, Burris HA, Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer. 2013;13:421-432. Abstract
Jerusalem G, Mariani G, Ciruelos EM, et al. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded access multicenter trial (BALLET). Annals of Oncology. 2016;27:1719-1725. Abstract
Ibrance® [package insert]. New York, NY: Pfizer Inc.; 2016.
Ibrance® [package insert]. Sandwich, Kent, UK: Pfizer Inc.; 2016.
Kisqali® [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; 2017.
Cardoso F, Villanueva C, Royce M, et al. Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): first- and second-line data from the BOLERO-4 study. Presented at: American Society of Clinical Oncology (ASCO); June 2-6, 2017; Chicago, IL. Abstract 1010.
Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet. 2016;388:2997-3005.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderator

Joseph Gligorov, MD, PhD

Professor of Medical Oncology, Medical Oncology Department; Head of Breast Cancers Expert Center, APHP, Tenon Hospital, IUC-UPMC, Sorbonne University, Paris, France

Disclosures

Joseph Gligorov, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Served as a speaker or a member of a speakers bureau for: Eisai Co., Ltd; Genomic Health; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Received grants for clinical research from: Eisai Co., Ltd; Genomic Health; Roche

Faculty

Guy Jerusalem, MD, PhD

Head, Medical Oncology, Department of Medicine; Director, Breast Clinic, Sart Tilman University Hospital; Professor of Medical Oncology, Liège University, Liège, Belgium

Disclosures

Disclosure: Guy Jerusalem, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Puma Biotechnology; Roche
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Received grants for clinical research from: Amgen Inc.; Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; Roche

Miguel Martin, MD, PhD

Professor of Medicine; Head, Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain

Disclosures

Disclosure: Miguel Martin, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca; Novartis Pharmaceuticals Corporation
Received grants for clinical research from: Novartis Pharmaceuticals Corporation

Editor

Deborah Middleton, MS

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Content Reviewer

Amy H. Seung, PharmD, BCOP

Disclosures

Disclosure: Amy H. Seung, PharmD, BCOP, has disclosed no relevant financial relationships.

CPD

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion

Authors: Joseph Gligorov, MD, PhD; Guy Jerusalem, MD, PhD; Miguel Martin, MD, PhD
CPD Released: 6/27/2017
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 6/27/2018, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically hematologists and oncologists involved in the treatment of patients with breast cancer.

The goal of this activity is to improve physicians' understanding regarding the treatment and management of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

Upon completion of this activity, participants will:

Have increased knowledge regarding the:

Clinical data supporting the use of agents targeting cyclin-dependent kinase 4/6 (CDK4/6) in patients with advanced, HR-positive breast cancer

Have greater competence related to:

The selection of first- and second-line therapy based on patient, disease, and clinical factors
Optimal management strategies for treatment-emergent side effects associated with CDK4/6 inhibitors to optimize tolerability, quality of life, and patient compliance
The selection of first- and second-line therapy based on patient, disease, and clinical factors

Disclosures

Moderator

Joseph Gligorov, MD, PhD

Professor of Medical Oncology, Medical Oncology Department; Head of Breast Cancers Expert Center, APHP, Tenon Hospital, IUC-UPMC, Sorbonne University, Paris, France

Disclosures

Joseph Gligorov, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Served as a speaker or a member of a speakers bureau for: Eisai Co., Ltd; Genomic Health; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Received grants for clinical research from: Eisai Co., Ltd; Genomic Health; Roche

Faculty

Guy Jerusalem, MD, PhD

Head, Medical Oncology, Department of Medicine; Director, Breast Clinic, Sart Tilman University Hospital; Professor of Medical Oncology, Liège University, Liège, Belgium

Disclosures

Disclosure: Guy Jerusalem, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Puma Biotechnology; Roche
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Received grants for clinical research from: Amgen Inc.; Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; Roche

Miguel Martin, MD, PhD

Professor of Medicine; Head, Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain

Disclosures

Disclosure: Miguel Martin, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca; Novartis Pharmaceuticals Corporation
Received grants for clinical research from: Novartis Pharmaceuticals Corporation

Editor

Deborah Middleton, MS

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Content Reviewer

Amy H. Seung, PharmD, BCOP

Disclosures

Disclosure: Amy H. Seung, PharmD, BCOP, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion

Authors: Joseph Gligorov, MD, PhD; Guy Jerusalem, MD, PhD; Miguel Martin, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 6/27/2017

Valid for credit through: 6/27/2018, 11:59 PM EST

processing....

CPD Information Download Slides

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Joseph Gligorov, MD, PhD

Faculty

Guy Jerusalem, MD, PhD

Miguel Martin, MD, PhD

Editor

Deborah Middleton, MS

Content Reviewer

Amy H. Seung, PharmD, BCOP

CPD

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion

Target Audience and Goal Statement

Disclosures

Moderator

Joseph Gligorov, MD, PhD

Faculty

Guy Jerusalem, MD, PhD

Miguel Martin, MD, PhD

Editor

Deborah Middleton, MS

Content Reviewer

Amy H. Seung, PharmD, BCOP

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion